SLN•benzinga•
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga